Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Computers in the Examination Room

Computers in the Examination Room Letters 2. Charytan D, Kuntz RE. The exclusion of patients with chronic kidney disease issue guidelines on the inclusion of women in clinical trials. from clinical trials in coronary artery disease. Kidney Int. 2006;70(11):2021-2030. Given that KD is highly prevalent and may modify relevant 3. Konstantinidis I, Nadkarni GN, Yacoub R, et al. Representation of patients parameters of some medications or procedures (eg, efficacy, with kidney disease in trials of cardiovascular interventions: an updated safety, and pharmacokinetics), patients with KD should be in- systematic review [published online November 30, 2015]. JAMA Intern Med. cluded in cardiovascular trials in the absence of absolute con- doi:10.1001/jamainternmed.2015.6102. traindications. Investigators’ goal should be to enroll a study 4. Tomey MI, Winston JA. Cardiovascular pathophysiology in chronic kidney disease: opportunities to transition from disease to health. Ann Glob Health. population in which the prevalence and severity of KD match 2014;80(1):69-76. the prevalence and severity in the target population. Further- 5. Chertow GM, Normand SL, McNeil BJ. “Renalism”: inappropriately low rates more, investigators should consider stratifying treatment as- of coronary angiography in elderly individuals with renal insufficiency. J Am Soc signment based on kidney function to achieve balance and Nephrol. 2004;15(9):2462-2468. should report outcome and http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Internal Medicine American Medical Association

Computers in the Examination Room

Frankel, Richard M.
JAMA Internal Medicine , Volume 176 (1) – Jan 1, 2016
Download PDF
5 pages

Loading next page...
 
/lp/american-medical-association/computers-in-the-examination-room-FMe1EFhYtk

References (13)

Publisher
American Medical Association
Copyright
Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6106
eISSN
2168-6114
DOI
10.1001/jamainternmed.2015.6559
pmid
26619228
Publisher site
See Article on Publisher Site

Abstract

Letters 2. Charytan D, Kuntz RE. The exclusion of patients with chronic kidney disease issue guidelines on the inclusion of women in clinical trials. from clinical trials in coronary artery disease. Kidney Int. 2006;70(11):2021-2030. Given that KD is highly prevalent and may modify relevant 3. Konstantinidis I, Nadkarni GN, Yacoub R, et al. Representation of patients parameters of some medications or procedures (eg, efficacy, with kidney disease in trials of cardiovascular interventions: an updated safety, and pharmacokinetics), patients with KD should be in- systematic review [published online November 30, 2015]. JAMA Intern Med. cluded in cardiovascular trials in the absence of absolute con- doi:10.1001/jamainternmed.2015.6102. traindications. Investigators’ goal should be to enroll a study 4. Tomey MI, Winston JA. Cardiovascular pathophysiology in chronic kidney disease: opportunities to transition from disease to health. Ann Glob Health. population in which the prevalence and severity of KD match 2014;80(1):69-76. the prevalence and severity in the target population. Further- 5. Chertow GM, Normand SL, McNeil BJ. “Renalism”: inappropriately low rates more, investigators should consider stratifying treatment as- of coronary angiography in elderly individuals with renal insufficiency. J Am Soc signment based on kidney function to achieve balance and Nephrol. 2004;15(9):2462-2468. should report outcome and

Journal

JAMA Internal Medicine – American Medical Association

Published: Jan 1, 2016

There are no references for this article.